Carboxylic acids and salts or anhydrides thereof (A61K47/12)

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex

Stable liquid pharmaceutical preparations of fused protein tnfr: fc // 2614257
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.50 cl, 1 dwg, 17 tbl, 3 ex

Tablets of clozapine with sustained release // 2613192
FIELD: pharmacy.SUBSTANCE: group of inventions relates to a pharmaceutical formulation of clozapine with sustained release in the form of tablets, film coated, containing 30.0-50.0 wt % of clozapine, 20.0-30.0 wt % of microcrystalline cellulose, 4.0-6.0 wt % of lactose monohydrate, 15.0-25.0 wt % of hydroxypropyl methylcellulose HPMC K15M, 1.0-3.0 wt % of hydroxypropyl methylcellulose HPMC 2910, 1.0-3.0 wt % of colloidal silicon dioxide, 0.05-1.5 wt % of pharmaceutically acceptable salts of stearic acid and 2.0-4.0 wt % of film coating which comprises polyvinyl alcohol, titanium dioxide, macrogol and acceptable dyes or a mixture Opadry II yellow; as well as to a process for preparing such a pharmaceutical composition.EFFECT: obtaining a stable pharmaceutical composition of clozapine in the form of tablets with sustained release and stable technological properties, as well as reproducible release kinetics of the active substance.9 cl, 5 ex, 1 tbl, 2 dwg
ethod for preparation of drug with locally-acting erythropoietin // 2611401
FIELD: medicine.SUBSTANCE: for method implementation, a film mass containing: 20.0 g of Na CMC 3% aqueous solution; 1.5 g of glycerol; 0.5 g of PEG 400; 0.006 g sorbic acid; EPO 1000 ME, is prepared. The film is stirred, poured into a mold and allowed to dry for 72 hours at the room temperature. The film is firmly fixed on the wound surface, absorbs the fluid, creating a moist environment in the wound, thereby facilitating early granulation. Plasticity provides atraumatic effect.EFFECT: potentiation of therapeutic effect, reduced microbial contamination, exact dosage of drug, which eliminates the possibility of overdoses and unwanted side effects.7 ex, 2 tbl
Water-soluble composition, possessing anti-tumour activity and method for obtaining thereof // 2611362
FIELD: medicine.SUBSTANCE: composition contains, wt %: soloxolon methyl 4.0-40.0; PEG with molecular weight 4000 Da - 40.0-57.4; β-glycine - 10.0-56.0. The invention also deals with method for obtaining composition, the method includes dissolution of soloxolon methyl and PEG in tert-butyl alcohol with ultrasonic impact and simultaneous heating of mixture to 45-50°C for 5-30 minutes until components are completely dissolved, after that addition of β-glycine and re-exposure of mixture to ulrrasound for 7-10 min, freezing and exposure of the obtained suspension at temperature -20°C for 4 hours, with the following lyophilic drying first at temperature -20°C until pressure in chamber drops lower than 17 mtorr, then at temperature 30°C for 2 hours.EFFECT: increase of water-solubility and anti-tumour activity of composition.2 cl, 3 dwg, 2 tbl, 7 ex

Compositions of recombinant furine // 2610436
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns stabilized aqueous compositions of recombinant furine, wherein compositions contain recombinant furine, pharmaceutically acceptable salt, calcium, sugar or sugar alcohol, non-ionic surfactant and buffer substance.EFFECT: group of inventions provides preserving more furine activity and content of monomer furine at simultaneous reduction of aggregation during storage and/or action of mechanical load.42 cl, 49 dwg, 22 tbl, 8 ex

Liquid dosage form of fenspiride and production method thereof // 2607965
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and represents liquid dosage form of fenspiride hydrochloride in form of syrup, including fenspiride hydrochloride, methyl parahydroxybenzoate, propyl parahydroxybenzoate, potassium sorbate, sodium citrate, citric acid monohydrate, sodium saccharinate, noncrystallizing liquid sorbitol, glycerin, honey flavoring agent, fruit flavoring agent, dye E110 and purified water, wherein ingredients of the dosage form are taken in certain proportions, g/100 ml.EFFECT: invention provides extending range of medications, which are liquid dosage forms of fenspiride hydrochloride, stable and long-term storable without use of sucrose.2 cl, 14 dwg, 9 tbl
Liquid pharmaceutical composition containing nitizinone // 2605301
FIELD: medicine.SUBSTANCE: invention refers to medicine and concerns liquid pharmaceutical composition applicable for oral administration, which involves suspension of effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitizinone) and buffer based on citric acid with pH in range from 2.5 to 3.5. Said composition is used for treating disorders and diseases, in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, for example, genetic tyrosinemia type I.EFFECT: invention provides stable liquid composition of nizitinone, which is adapted for introduction in children.20 cl, 7 ex, 12 tbl

Live vaccine for preventing influenza and preparation method thereof // 2604414
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and is designed to manufacture liquid form influenza vaccine. Live vaccine in liquid form for preventing influenza includes flu strains of type H1N1 H3N2, B and a stabilizer. Stabilizer is represented by a complex consisting of gelatin, disodium salt of ethylenediamine tetraacetic acid with maltose, at the following content in a 0.5 mg dose: flue strain of subtype H1N1 and H3N2 with specific activity of not less than 106.9 EID50; flue strain of type B with specific activity of not less than 106.4 EID50; gelatine - 4.5-5.5 mg; disodium salt of ethylenediamine tetraacetic acid - 0.045-0.055 mg; maltose - 0.45-0.55 mg. Group of inventions also relates to a method for producing the said influenza vaccine.EFFECT: use of this group of inventions enables to obtain a live influenza vaccine in liquid form with high degree of purification from ovalbumin and impurity proteins, as well as promotes preservation of specific activity of vaccine during storage.2 cl, 2 tbl

ethod of producing water-soluble lyophilisate of 4-(3-oxo-3-ethoxypropanoyl)amino)benzoic acid possessing anti-ischemic and antioxidant activity // 2602665
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a method of producing a water-soluble lyophilisate, involving producing a combined solution of an active substance and a compound containing hydroxyl and amino groups (amino alcohol), characterized by that the active substance is 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid (EPABA) possessing anti-ischemic and antioxidant activity. Amino alcohol is selected from a group of N-methylglucamine or tris(hydroxymethyl)aminomethane; herewith the said substance and amino alcohol taken in the molar ratio from 1:1 to 1:10 are dissolved in water, the solution is added with an acid agent up to pH 6.8-7.5, neutral solution is filtered, frozen and dried by sublimation.EFFECT: invention enables to obtain water-soluble stable neutral lyophilisates of EPABA corresponding to process requirements of preparations for parenteral administration.3 cl, 4 dwg, 4 tbl, 2 ex

Drug preparation based on indole-3-carbinol with increased epigenetic activity // 2601893
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and can be used for production of medicinal agents, required in therapy of diseases of the reproductive system (pathology of mammary glands, uterus, endometrium). Therapeutic agent possessing epigenetic activity contains indole-3-carbinol and excipients: lactose, microcrystalline cellulose, modified corn starch, magnesium stearate or calcium stearate, enclosed in a capsule, which are made from hydroxypropyl methylcellulose, in the following quantity in one capsule, g: indole-3-carbinol 0.10-0.20; lactose 0.10-0.15; corn starch modified 0.05-0.15; microcrystalline cellulose 0.5-0.15; magnesium stearate or calcium stearate 0.001-0.004.EFFECT: invention allows to increase efficiency of release of indole-3-carbinol of dosage form and its conversion into diindolylmethane, which implements its diindolylmethane activity.1 cl, 3 dwg, 4 ex

Tableted drug based on the extract of alchemilla vulgaris // 2599020
FIELD: medicine.SUBSTANCE: invention relates to tableted drug for the treatment of syndrome of increased blood viscosity. Agent includes 6 wt% of thick extract of Alchemilla vulgaris, obtained by evaporation of alcoholic extract to a residual humidity of 25 %, 46.8 wt% of glucose, 46.8 wt% of lactose, 0.1 wt% of calcium stearate and 5 % aqueous solution of methylcellulose - the rest.EFFECT: invention ensures production of tablets with high strength, high stability during storage and satisfying the requirements of the current pharmacopoeia.1 cl, 2 tbl, 1 ex

Agent with immunomodulating properties for prevention of atherosclerosis // 2597161
FIELD: medicine.SUBSTANCE: invention relates to an agent with immunomodulating properties for prevention of atherosclerosis. Above agent contains 21 wt% of dried garlic powder, 21 wt% of dried Rhaponticum carthamoides powder, 21 wt% of powder of dried green tea leaves, 24 wt% of milk sugar (lactose), 7.8 wt% of stearic acid and 5.2 wt% of medical polyvinylpyrrolidone.EFFECT: invention has immunomodulatory action, which manifests itself in depolarisation of macrophages, hypolipidemic action, antioxidant activity and thrombolytic action.1 cl, 2 dwg, 2 tbl

Lyophilised preparation of cytotoxic dipeptides // 2597154
FIELD: pharmaceutics.SUBSTANCE: invention relates to a novel pharmaceutical Lyophilised preparation containing cytotoxic dipeptide, such as melphalan ftorfenamid hydrochloride, and saccharose, methods for preparing it, compositions containing Lyophilised pharmaceutical preparation and use thereof in treating malignant tumours.EFFECT: new preparation.15 cl, 21 dwg, 14 tbl, 5 ex

Pharmaceutical compositions containing dgat1 inhibitor // 2595866
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition in form of a tablet containing a) therapeutically effective amount of sodium salt (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, b) sodium lauryl sulphate as a surfactant with properties of lubricant substance in amount of 0.1 to 5 %, c) low-substituted hydroxypropyl cellulose in dry binder with properties of baking powder in amount of 2 to 20 %, d) mixture of microcrystalline cellulose and anhydrous lactose as filler in ratio of 1:5 to 1:1 and e) sodium starch glycolate as a disintegrant in amount of 1 to 10 % by weight of tablet before application of film coating. Invention also relates to a method of preparing a pharmaceutical composition and use thereof as a medicinal agent.EFFECT: compositions demonstrate compression profile with a wide hardness window, which provides acceptable brittleness, hardness, decomposition and dissolution time and sufficient stability to achieve rational storage life.10 cl, 10 ex

Antiviral and immunostimulating drug // 2593570
FIELD: pharmaceutics. SUBSTANCE: described are 3 versions of antiviral and immunostimulating drugs in form of a film-coated tablet, consisting of active substance methylphenylthiomethyl-dimethylaminomethyl-hydroxybromoindole carboxylic acid ethyl ester (umifenovir), auxiliary substances of tablet-core and film shell. EFFECT: higher storage stability of said drug. 18 cl, 4 tbl

Drug dosage form containing 6'-fluoro-(n-methyl-or n, n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1, 1'-pyrano[3, 4, b]indole]-4-amine // 2589830
FIELD: medicine.SUBSTANCE: invention relates to medicine. Disclosed is a therapeutic dosage form for pain management, which contains 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'N-spiro[cyclohexane-1,1'-pirano [3,4,b]indole]-4-amine or its physiologically acceptable salt and self-emulsifying preparation containing surfactant having hydrophilic-lipophilic balance (HLB) at least of 10 and oil, wherein oil is selected from group comprising saturated C8-C14 fatty acids, unsaturated C8-C18 fatty acids and their esters, mixture of saturated and unsaturated C8-C14 fatty acids, triglycerides of fatty acids, esters of propylene glycol and fatty acid. Drug dosage form is intended for introduction of twice a day, once a day or less frequently.EFFECT: technical result consists in the immediate release 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'N-spiro[cyclohexane-1,1'-pirano[3,4,b]indole]-4-amine of the dosage form, in good bioavailability, despite low solubility in water and providing a long period of semi-elimination from body.13 cl, 1 dwg, 28 tbl

Pharmaceutical composition for oral administration with improved solubility and/or absorbability // 2589701
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition for oral administration containing 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide, its salt or solvate as active pharmaceutical ingredient and fumaric acid as acid additive. Fumaric acid is contained in an amount of 0.25 to 5 weight fractions on the weight ratio of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamid.EFFECT: also described is method of stabilization, improve solubility and improved intestinal absorption of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide by adding of fumaric acid to pharmaceutical composition.12 cl, 5 dwg, 8 tbl, 9 ex

Stable composition of antibody specifically bound with her2 receptors and preparation method thereof // 2589691
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and biotechnology, namely concerns new stable composition of antibody specifically bound with HER2 receptors in dried form, which can be recovered by solvent, and in form of concentrated solution, as well as method for preparing composition.EFFECT: invention can be used for creation of finished dosage form of preparation, as well as for preparing solution for infusions used for treating HER2-positive tumours.9 cl, 1 dwg, 3 tbl, 21 ex

Tablet quetiapine with prolonged release and synthesis method thereof // 2588840
FIELD: medicine; pharmaceuticals.SUBSTANCE: pharmaceutical composition in the form of pellets, characterised by that it has a coating containing copolymer of methacrylic acid and ethyl acrylate (1:1) and triethyl citrate, applied on a core consisting of the internal phase containing quetiapine fumarate or quetiapine, copolymer of methacrylic acid and ethyl acrylate (1:1), lactose, anhydrous crystalline maltose, and external phase containing talc and magnesium stearate. Method involves double wet granulation, drying, addition of lubricating and sliding substances, pressing and application of coating on the ready tablet.EFFECT: tablet atypical antipsychotic agents are effective and stable during storage.2 cl, 7 tbl, 6 ex

Biodegradable particles, material for vascular occlusion and method of producing biodegradable particles // 2587326
FIELD: medicine.SUBSTANCE: invention refers to medicine and is in biodegradable particles for use as material for embolisation of vessels. Particles are obtained by dissolving synthetic polymer poly basic carboxylic acid and condensation of water-soluble carbodiimide in aprotic organic solvent, addition of obtained solution in droplets to bad solvent for said aprotic polar solvent and by chemical linking reaction in obtained drops. Water content in particles makes 20-90 % in water-saturated state. Invention also relates to method of producing said particles and to material for embolisation vessels.EFFECT: technical result consists in fact that they have improved flexibility, brought to smaller aggregation between particles and can be easily delivered to selected point in blood vessel, without causing clogging of catheter; besides, particles retain shape that allows efficiency cause embolisation.10 cl, 1 tbl, 10 ex

Pharmaceutical composition containing biopharmaceutical drug // 2587056
FIELD: medicine; pharmacology.SUBSTANCE: group of inventions refers to Pharmacology and medicine and concerns stable pharmaceutical composition containing antibody against TNF-alpha and adipic acid or adipate, as well as using said composition for treating at least, one of the pathological state, selected from group including autoimmune diseases, infectious diseases, neoplastic disease, diseases of nervous system.EFFECT: group of inventions provides reduced aggregation antibodies in aqueous solutions and high stability during storage.9 cl, 13 tbl, 4 dwg

ethod for producing carrier particles for dry powders for inhalations // 2585101
FIELD: medicine.SUBSTANCE: described are carrier particles, a method for producing a carrier for a dry power pharmaceutical composition for inhalations, as well as the pharmaceutical composition in the form of a dry powder for inhalations. The active composition contains an active ingredient and carrier particles. The above carrier particles represent an alpha-lactose monohydrate with the mass diameter from 900 to 400 microns and are magnesium stearate-coated. The carrier particles are prepared by the method according to which the coating is deposited by a dry process in a mixer granulator with a high shear force at a rotational speed of 500 to 1,500 rpm.EFFECT: composition homogeneity in the environment comparable to that may occur when in use, the stronger adhesion of magnesium stearate to the particle carrier surface during inhalation, and therefore not suitable for systemic absorption that further increases the powder safety.13 cl, 13 tbl, 8 ex, 3 dwg

Composite collagen sponge and method of making same // 2584348
FIELD: medicine.SUBSTANCE: invention relates to medicine. Composite collagen sponge is intended for bleeding control, as well as for stimulation of growth and cell proliferation. Sponge comprises collagen, cell growth factors, and a protecting agent in an amount of 10-50 wt%, where protective agent contains amino acids, saccharides and albumin in weight ratio of 1-11:1.25-17.5:1-7.5. Method of producing sponge involves a step for virus inactivation, which includes two steps: first step is a viral inactivation organic solvent/detergent; second step is 30-120-minute solution treatment sponge on a water bath at 90-100 °C, and is carried out in presence of a protective agent. Sponge may be subjected to viral inactivation for a long time at high temperature, while bioactivity of collagen and growth factors is maintained.EFFECT: technical result consists in that sponge has water-absorbing capacity of more than 52 times based on weight of sponge and has modulus of elasticity greater than 70 N/cm2.7 cl, 3 ex, 11 tbl, 3 dwg

Using magnesium stearate in dry inhalation powder formulations // 2580890
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine. What is described is the use of magnesium stearate in an inhalation powder formulation containing carrier particles to inhibit or reduce chemical degradation of the active ingredient containing a hydrolysis-sensitive group. The active ingredient is specified in classes consisting of antimuscarinics, phosphodiesterase-4 inhibitors and steroids.EFFECT: in presence of magnesium stearate, the active ingredients have higher chemical storage-stability, particularly at high temperatures and/or high percentage of moisture.7 cl, 2 dwg, 3 tbl, 1 ex

Aerosol preparation based on fenoterol hydrobromide for treating respiratory diseases // 2577289
FIELD: medicine.SUBSTANCE: invention refers to medicine and pharmaceutical industry and concerns composition and method of producing the preparation of highly effective pharmaceutical substance and excipients allowing to form a fine particle aerosol to penetrate into the bronchi and pulmonary alveoli. Inhalation formulation for treating bronchial asthma and chronic obstructive pulmonary disease, containing as active component fenoterol hydrobromide, as a solvent-pure ethyl alcohol, a propellant, the propellant contains HFA-134a and/or HFA-227ea, as well as additionally contains an acidity regulator selected from hydrochloric acid, phosphoric and citric acids, as a substance which regulates the distribution profile, triethyl citrate.EFFECT: invention provides higher respirable fraction up to 35-40 % and obtaining optimum distribution profile of particles.2 cl, 1 dwg, 4 ex

Transdermally absorbable medicinal product // 2576612
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine. What is described is a transdermally absorbable medicinal product containing 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}benamidine or its salt, and a transdermal absorption enhancer.EFFECT: transdermally absorbable medicinal product effective in treating fungal infections, possesses a very high ability of for skin penetration and high antifungal activity; and the medicinal product significantly improves the patient's quality of life.13 cl, 2 dwg, 7 tbl, 58 ex

Pharmaceutical composition including amide derivative or pharmaceutically acceptable salt thereof // 2575829
FIELD: chemistry.SUBSTANCE: pharmaceutical composition includes a compound of formula (I) or a pharmaceutically acceptable salt thereof, an acid additive and inert filler. As the acid additive alginic acid or silicon dioxide is used.EFFECT: enhanced storage stability of the specified composition.9 cl, 19 ex, 7 tbl, 4 dwg
Agent for treating and preventing viral skin new growths // 2574953
FIELD: medicine.SUBSTANCE: what is described is an antiviral emulsion agent based on interferon inducer for topical application. The base contains Vaseline or Vaseline oil, T-2 emulsifier, as well as a solution of amphiphilic complex or single-chain high-polymeric RNA of Saccharomyces cerevisiae containing short double-stranded regions with oleic acid enriched with sodium oleate (up to 10%).EFFECT: prolonging the shelf life of the above agent.1 ex

ethod and formulation for producing 99m tc labelled 5-thio-d-glucose agent for radionuclide diagnosis // 2568888
FIELD: medicine.SUBSTANCE: method for producing 99m Tc-labelled 5-thio-D-glucose agent for radionuclide diagnosis involves producing a reaction mixture consisting of glucose derivative, tin (II) chloride dehydrate, hydrochloric acid and ascorbic acid in 1 ml of the solution, filtering and sterilising the produced solution and lyophilising the agent and sealing it in a bottle; the mixture is lyophilised without pre-freezing in liquid nitrogen. The reaction mixture contains 5-thio-D-glucose and water for injections in the following proportions: 5-thio-D-glucose 15 mg, tin (II) chloride dehydrate 0.150-0.175 mg, 0.05 M hydrochloric acid 200 mcl (0.36 mg), ascorbic acid 0.5 mg and water for injections 1 ml.EFFECT: creating the standard storage-stable formulation for producing the 99mTc-5-thio-D-glucose radiopharmaceutical to image a tumour by means of SPECT gamma-chamber and visualise biochemical changes of metabolism that is expected to promote accurate diagnosing and effective treatment of tumours.2 cl, 2 ex, 3 dwg, 1 tbl

Oxidation stable and breaking resistance dosage form // 2567723
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to thermally moulded pharmaceutical dosage form, which has a breaking resistance of at least 300 N, and to a method for producing it. The above dosage form contains a pharmacologically active ingredient (A) specified in morphine, hydromorphine, oxycodone, oxymorphone, (1R,2R-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and their pharmaceutically acceptable salts, a free physiologically acceptable acid (B) in an amount of 0.3±0.18 wt % at total weight of the pharmaceutical dosage form, an antioxidant in an amount of 0.001 wt % to 5.0 wt % at total weight of the pharmaceutical dosage form and polyalkylene oxide (C), which has an average molecular weight Mw of at least 200.000 g/mol. A method for producing the above dosage form involves mixing all the ingredients, heating to a melting point of polyethylene oxide (C), extruding through an extruder outlet, separating plastic extrudate and moulding the pharmaceutical dosage form or cooling.EFFECT: increasing the storage-stability of the pharmaceutical dosage form.13 cl, 1 dwg, 9 ex

Pharmaceutical composition for treating mycotic diseases // 2563811
FIELD: medicine.SUBSTANCE: as an active substance, a formulation according to the invention contains 3-ethoxyxycarbonyl-5-(4-chlorobenzylidene)thiazolidine-2,4-dione 2-5 wt %, and also the pharmaceutical composition is expected to contain carbamide in an amount of 2.5-4.0 wt %, as a keratolytic agent. The ointment also contains a lipophilic base that is petroleum paraffin wax in an amount of 5-7 wt %, stearic acid 2-6.5 wt %, emulsion wax 8-12 wt %, a target additive - benzoic acid 0.1-2 wt % and Vaseline oil up to 100%. The pharmaceutical formulation is produced by fusing the solid ingredients of the base, adding concentrated 3-ethoxyxycarbonyl-5-(4-chlorobenzylidene)thiazolidine-2,4-dione in Vaseline oil and carbamide in Vaseline oil.EFFECT: producing the pharmaceutical formulation possessing the high chemotherapeutic efficacy and good tolerance, low toxicity that makes it applicable in treating dermatomycosis of different localisation.2 cl, 3 tbl
Film-generating composition for application of coatings based on solid powder-like compounds // 2563133
FIELD: chemistry.SUBSTANCE: claimed is a film-generating composition for the application of a film coating on pharmaceutical tablets, food additives, confectionary products, etc. The film-generating composition for the coating application includes a water-soluble film-generating agent, such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, starches, modified startches, etc., and one or more hydrophobic compounds, such as a salt of a metal of higher fatty acids, higher fatty alcohol, natural wax from a vegetable or animal source or synthetic wax. The film-generating composition for the coating application can optionally contain plasticisers, colouring substances, such as pigments, and/or fluidity-improving compounds.EFFECT: composition improvement.10 cl, 12 ex, 1 tbl
Pharmaceutical compositions based on n-carbamoyl-methyl-4-phenyl-2-pyrrolidone // 2560691
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of medicine, pharmacology and chemical-pharmaceutical industry and deals with medications which influence neurological and mnestic functions in people. Target of claimed invention consists in development of stable, economically expedient, industrially realisable, preparative form of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone. Set task is solved by mixing N-carbamoyl-methyl-4-phenyl-2-pyrrolidone and selected pharmaceutically acceptable additional substances with water.EFFECT: creation of drug form in such form makes it possible to extend technological possibilities and economical expediency of finished medication production.9 cl, 4 ex

isuse protected dosage form for oxidation sensitive opioids // 2555531
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to thermoformed pharmaceutical dosage form having a minimum tensile strength of 300 N; the above dosage form contains an opioid, a free physiologically acceptable carboxylic acid in an amount from 0.1 to 5.0 wt %, at total weight of the pharmaceutical dosage form and polyalkylene oxide having a minimum average molecular weight Mm of 500,000 g/mole. Carboxylic acid is specified in a group consisting of maleic acid, fumaric acid, glutaric acid, malonic acid and citric acid. The opioid is specified in a group consisting of oxymorphone, oxycodone, hydromorphone and their physiologically acceptable salts. The pharmaceutical dosage form can be packaged.EFFECT: pharmaceutical dosage for according to the invention is characterised by the improved storage stability.14 cl, 11 tbl, 9 ex

Set for preservation of native erythrocytes // 2554764
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to immunology, and describes set for preservation of native erythrocytes, applied for detection of antibodies to antigens of erythrocytes, consists of two solutions: water solution for short-term stay of erythrocytes, which contains 9.0-11.0 g/l of glucose, 0.2-0.3 g/l of sodium citrate, 0.01-0.02 g/l of citric acid and 0.95-1.05 g/l of bull serum albumin, and water solution for storing erythrocytes, which includes 0.2-0.4 g/l of adenine, 25.0-35.0 g/l of glucose, 6.0-8.0 g/l of mannitol, 0.2-0.3 g/l of sodium citrate, 0.05 -0.07 g/l of citric acid and 0.95-1.05 g/l of bull serum albumin.EFFECT: invention ensures preserving ability of antigens of membrane of preserved native erythrocytes to bind with respective clinically significant antibodies for term not less than 2 months.3 cl, 1 tbl

Pharmaceutical composition containing rabeprazole and method for producing it // 2554735
FIELD: medicine.SUBSTANCE: pharmaceutical composition in the form of a tablet contains a core coated with a separating layer and an enteric coating. The core contains an active substance, sodium rabeprazole, and additives - calcium carbonate, lactose, starch, hydroxypropylmethyl cellulose, stearic acid salt in the amounts specified in the patent claim. What is also described is a method for producing the pharmaceutical composition of rabeprazole. The invention enables to extend the range of medical products applicable for treating gastric ulcer.EFFECT: low in foreign impurities and having good stability.3 cl, 3 tbl, 5 ex

Pharmaceutical compositions and respective delivery methods // 2552324
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.EFFECT: group of inventions relates to improvement of octreotide bioavailability.100 cl, 39 ex, 10 dwg, 45 tbl
Pharmaceutical composition, possessing gaba-ergic activity // 2550960
FIELD: pharmacology.SUBSTANCE: invention relates to pharmaceutical composition, possessing GABA-ergic activity, which contains 4[(4'-nicotinoylamino)butyroylamino]butanic acid, nicotinoyl gamma-aminobutyric acid, calcium salt of homopantothenic acid, thiamine chloride (vitamin B1), riboflavin (vitamin B2), pyridoxine (vitamin B6), nicotinic acid (vitamin B3), nicotinamide (vitamin B3*) calcium pantothenate (B5), folic acid (vitamin B9), cyancobalamine (vitamin B12) and as additional substances talc, calcium stearate, magnesium stearate, starch-sugar granulate, or microcrystalline cellulose, or lactose, where vitamin B1 is present in form of double granulate with polyvinylpyrrolidone and starch-sugar paste.EFFECT: composition improvement.5 cl, 3 tbl, 10 ex
edication based on product of dry sublimation of hazel, possessing anti-inflammatory, bactericidal, antifungal and myotonic action // 2546013
FIELD: chemistry.SUBSTANCE: medication includes 7.0-9.0 wt % of a dried thick fraction of a product of hazel dry sublimation, 0.025-0.033 wt % of hydrochloride anaprilin, 36.0-38.0 wt % of sodium hydrocarbonate, 24.5-25.5 wt % of boric acid, 12.0-16.0 wt % of phthalic acid, 5.5-7.5 wt % of sodium carboxymethylcellulose, 0.8-1.0 wt % of sodium dodecylsulphate, 0.45-0.55 wt % of calcium stearate and 5.5-10.8 wt % of glucose.EFFECT: invention increases the therapeutic and preventive efficiency of treatment of postnatal endometritis in cows and cow-heifers.
Pharmaceutical composition in form of tablet and method of obtaining thereof // 2546002
FIELD: medicine.SUBSTANCE: composition includes glutaryl histamine in an amount of 18.0-75.0 wt % as an active substance, and as auxiliary substances: microcrystalline cellulose in an amount of 18.0-71.0 wt %, sodium croscarmellose in an amount of 0.25-1.0 wt %, colloidal silicon dioxide in an amount of 0.5-2.0 wt %, calcium stearate in an amount of 0.5-2.0 wt % and lactose monohydrate. The invention also relates to a method of obtaining the said composition.EFFECT: invention is characterised by the high bioavailability of the active component and high pharmacological activity.4 cl, 6 tbl, 3 ex
Percutaneously absorbable preparation // 2543639
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a percutaneously absorbable layer having a base and an adhesive layer which is placed on the base and which comprises an adhesive agent and a therapeutic ingredient. The adhesive agent contains a mixture of resins containing 100 portions by weight of an acrylic copolymer (A) and 0.1 to 30 portions by weight of an acrylic copolymer (B) or 0.05 to 2 portions by weight of a low-molecular polyamine compound having at least two amino groups in one molecule and non-polymerising with a polymer or an oligomer formed. The adhesive layer additionally contains an organic acid. The acrylic copolymer (A) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains 3 to 45 wt % of diacetone acrylamide as a target monomer ingredient, but free from a free carboxylic group. The acrylic copolymer (B) represents an acrylic copolymer, which contains acrylic ester of (meth)acrylic acid as a main monomer ingredient and contains a primary amino group and/or carboxyhydrazidase group on side chains, but free from a free carboxylic group.EFFECT: reducing the aging period of the adhesive layer considerably.7 cl, 8 tbl, 39 ex
Pantocalcin, nootropic agent in liquid form // 2542419
FIELD: medicine.SUBSTANCE: invention represents a liquid dosage form of a hopantenic acid calcium salt possessing nootropic activity, containing an effective amount of the hopantenic acid calcium salt and additive agents. It represents drops, and as additive agents, it contains benzoic acid, sodium saccharinate, an orange flavour, hydrochloric 1M, Trilon B and water.EFFECT: higher active substance content by improving its organoleptic properties and reducing a viscosity of the liquid dosage form by reducing the content of viscosity-enhancing agents and increasing the water content.2 cl, 4 ex
Dosage form of clopidogrel // 2540519
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a dosage form of Clopidogrel presented in the form of a solid gelatine capsule. The dosage form contains Clopidogrel hydrogen sulphate, lactose anhydride, microcrystalline cellulose, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate.EFFECT: according to the invention, the dosage form of Clopidogrel contains a high amount of the active ingredient; it is prepared without the use of a wet granulation technique, and provides the more accurate dosage of the ingredients and the stability of the substances used.9 tbl

Highly dispersive pharmaceutical composition of budesonide with beta-glycine and method of obtaining thereof // 2539376
FIELD: chemistry.SUBSTANCE: highly dispersive pharmaceutical composition contains from 5 to 100 mg of budesonide per 1 g of β-glycine. Composition is characterised by bulk density 0.008-0.035 g/cm3 and consists of porous spherical agglomerates with diameter to 50 mcm and separate fragments, formed in the process of destruction of agglomerates, which represent complex of joined into perforated layers separate particles. Composition is obtained by method, based on dispersing into tank with liquid nitrogen solutions of initial substances in mixed solvent tetrahydrofurane-water, in which concentration of tetrahydrofurane constitutes 20-25 wt %, solvents are removed from obtained by dispersion mixture of solid phases in dry nitrogen flow under pressure 100 Pa until pressure drop less than 2 Pa by step-by-step temperature increase in the interval from -196°C to -5°C to decompose clathrate hydrate formed in the system tetrahydrofurane-water and to remove components of used mixture of solvents by sublimation, then from -5°C to +30°C to remove residual moisture, with application of initial substances budesonide and α-glycine in mixed solvent tetrahydrofurane-water with ratio budesonide from 0.25 to 0.9 mg/g of solvent, α-glycine from 8 to 50 mg/g of solvent.EFFECT: improved method of composition obtaining.2 cl, 5 dwg, 2 tbl, 5 ex

Highly dispersed combined pharmaceutical composition of methazone and salbutamol with beta-glycine and method of obtaining thereof // 2539374
FIELD: chemistry.SUBSTANCE: as medications composition includes beclomethazone dipropionate and salbutamol, with beta-glycine serving as carrier. Composition is obtained by dispersing solutions of initial medications in mixed solvent into tank with liquid nitrogen with further removal of solvents from obtained by dispersion mixture solid phases in dry nitrogen flow under pressure 600±20 mtorr to pressure drop less than 8 mtorr with stopping nitrogen supply by step-by-step increase of temperature: in the interval from -196°C to -15°C, then from -15°C to +30°C. As initial substances used are: beclomethazone dipropionate 1.9-5.1 wt %, salbutamol 1.9-10.2 wt %, alpha-glycin to 100%. Composition of mixed solvent includes tetrahydrofurane 5-15 wt %, tert-butyl alcohol 15-5 wt %, water 77-80 wt %.EFFECT: invention provides obtaining highly dispersed pharmaceutical composition of salbutamol and beclomethazone dipropionate.2 cl, 10 dwg, 3 tbl, 5 ex
Pharmaceutical composition containing sildenafil citrate, and method of using it // 2536425
FIELD: medicine.SUBSTANCE: invention refers to a new pharmaceutical composition in the form of spray for oral administration, containing an aqueous solution of sildenafil citrate as an active substance in the amount of 3-30 wt %. The composition contains stabilising agents in the form of pharmaceutically acceptable calcium salts taken in an amount required to reduce pH to 3.0 to 6.0. The calcium salts are specified in a group consisting of calcium lactate pentahydrate, calcium lactate trihydrate, calcium gluconate, calcium malate, calcium glycolate, calcium chloride hexahydrate and calcium chloride dihydrate. What is also described is a method for preparing the composition by introducing the pharmaceutically acceptable calcium salts as the stabilising agents into the aqueous solution of sildenafil citrate.EFFECT: pharmaceutical composition in the form of oral spray is free from organic solvents and applicably for sexual dysfunction.13 cl, 8 ex

Combined aerosol preparation for treating respiratory diseases // 2536253
FIELD: medicine.SUBSTANCE: as active ingredients, a formulation contains fenoterol hydrobromide and ipratropium bromide monohydrate; the excipients are absolute ethanol, triethylcitrate, propellant 1,1,1,4 tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA-227ea) and a pharmaceutically acceptable acid specified in hydrochloric, orthophosphoric and citric acids.EFFECT: increasing the respirable fraction and obtaining an optimised particle release profile.2 dwg, 6 ex

Dry glass-like composition for stabilisation and protection of biologically active material, and method for its obtaining // 2535869
FIELD: biotechnologies.SUBSTANCE: biologically active material, a matrix shaping agent and at least two glass-shaping agents are combined in a water solvent so that a viscous suspension is obtained. The obtained suspension is quickly frozen in liquid nitrogen with formation of solid frozen particles in the form of granules, drop particles or fibres. Frozen particles are degassed under vacuum gauge pressure of 0 to 2000 mTorr (266.6 Pa) and at the temperature below a composition freezing point during 1-30 minutes. Further, particles are subject to primary drying at the pressure of 2000 to 10000 mTorr (266.6 to 1333 Pa) and at the temperature above the particle freezing point. Secondary drying of particles is performed at full vacuum and temperature of 20°C to 70°C during the period of the time sufficient for reduction of activity of water of the obtained composition to Aw 0.3 or below.EFFECT: excluding boiling or excess foaming of a composition at simultaneous achievement of considerable acceleration of drying and high allowable load of the composition.11 cl, 9 dwg, 1 tbl, 16 ex
ethod of therapy of endometritis of cats and dogs // 2535092
FIELD: veterinary medicine.SUBSTANCE: method comprises administering an agent containing gentamicin, gamavit, sodium benzoate, potassium sorbate and propylene glycol. The agent is used in intrauterine mode 2 times a day for 7-10 days at a dose of 5-10 ml to cat and 10-20 ml to dog.EFFECT: method comprises high therapeutic efficacy in endometritis of cats and dogs.1 ex